Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
VC1-H82F6 | Human | Biotinylated Human VCAM-1 / CD106 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
VC1-H5253 | Human | Human VCAM-1 / CD106 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
VC1-H5224 | Human | Human VCAM-1 / CD106 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human VCAM-1, Fc Tag (Cat. No. VC1-H5253) at 5 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 5-156 ng/mL (QC tested).
The purity of Human VCAM-1, Fc Tag(Cat. No. VC1-H5253) is more than 85% and the molecular weight of this protein is around 204-260 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tocopherol acetate | DSE-9912 | Approved | National Institute Of Diabetes And Digestive And Kidney Diseases | Ephynal, Aquasol E | Mainland China | Basf Health & Nutrition As, Basf (China) Co Ltd Beijing Office | 2006-12-05 | Non-alcoholic Fatty Liver Disease; Venous Thromboembolism; Atherosclerosis; Intermittent Claudication; Thrombosis; Diabetic Retinopathy | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
99mTccAbVCAM1‐5 | 99mTccAbVCAM1‐5 | Phase 1 Clinical | Medico-Economic Evaluation Unit , University Hospital, Grenoble | Atherosclerosis | Details |
This web search service is supported by Google Inc.